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Treatment-free remission following frontline nilotinib in
patients with chronic myeloid leukemia in chronic phase:
results from the ENESTfreedom study
A Hochhaus1, T Masszi2, FJ Giles3, JP Radich4, DM Ross5, MT Gómez Casares6, A Hellmann7, J Stentoft8, E Conneally9,
V García-Gutiérrez10, N Gattermann11, W Wiktor-Jedrzejczak12, PD le Coutre13, B Martino14, S Saussele15, HD Menssen16, W Deng17,
N Krunic18, V Bedoucha16 and G Saglio19
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a
molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive
chronic myeloid leukemia in chronic phase with MR4.5 (BCR-ABL1⩽ 0.0032% on the International Scale (BCR-ABL1IS)) and ⩾ 2 years of
frontline nilotinib therapy were enrolled. Patients with sustained deep molecular response during the 1-year nilotinib consolidation
phase were eligible to stop treatment and enter the TFR phase. Patients with loss of major molecular response (MMR; BCR-
ABL1IS⩽ 0.1%) during the TFR phase reinitiated nilotinib. In total, 215 patients entered the consolidation phase, of whom 190
entered the TFR phase. The median duration of nilotinib before stopping treatment was 43.5 months. At 48 weeks after stopping
nilotinib, 98 patients (51.6%; 95% conﬁdence interval, 44.2–58.9%) remained in MMR or better (primary end point). Of the 86
patients who restarted nilotinib in the treatment reinitiation phase after loss of MMR, 98.8% and 88.4%, respectively, regained MMR
and MR4.5 by the data cutoff date. Consistent with prior reports of imatinib-treated patients, musculoskeletal pain-related events
were reported in 24.7% of patients in the TFR phase (consolidation phase, 16.3%).
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INTRODUCTION
Treatment-free remission (TFR; that is, sustained major molecular
response (MMR; BCR-ABL1⩽ 0.1% on the International Scale
(BCR-ABL1IS)) or deep molecular response (DMR) after stopping
tyrosine kinase inhibitor (TKI) therapy) is an emerging treatment
goal for patients with chronic myeloid leukemia in chronic phase
(CML-CP). Current recommendations of the European Leukemia-
Net call for indeﬁnite treatment with TKIs in responding patients,1
whereas the 2017 National Comprehensive Cancer Network
guidelines for CML note that discontinuation of TKI therapy is
feasible in selected patients in the context of careful monitoring.2
Patients may be motivated to stop therapy for reasons including
relief from treatment side effects, the ability to safely attempt
pregnancy or the desire for other potential improvements in
health-related quality of life.3–5 The potential for patients who
achieve DMR to remain in remission after stopping TKI therapy
was ﬁrst demonstrated in the Stop Imatinib 1 trial, in which ≈40%
of patients with sustained DMR (with undetectable BCR-ABL1 for
⩾ 2 years) on long-term imatinib maintained this response (no
conﬁrmed loss of undetectable BCR-ABL1) 1 year after stopping
treatment.6
Since the Stop Imatinib 1 trial, several additional trials have
investigated TKI discontinuation in patients with sustained DMR,
the majority of which involved patients treated with long-term
imatinib therapy.4,7–13 However, the European Stop Tyrosine
Kinase Inhibitor (EURO-SKI) study—the largest TFR trial to date10
—includes patients who achieved sustained DMR (speciﬁcally,
MR4 (BCR-ABL1IS⩽ 0.01%) for ⩾ 1 year) on imatinib, nilotinib or
dasatinib. Other ongoing trials are speciﬁcally investigating TFR
following treatment with second-generation TKIs, including the
STOP 2G-TKI study of patients with undetectable BCR-ABL1 for ⩾ 2
years on frontline or second-line nilotinib or dasatinib,14 the
Dasatinib Discontinuation study of patients on second- or later-
line dasatinib with DMR (BCR-ABL1o0.0069%) for ⩾ 1 year12 and a
series of four Evaluating Nilotinib Efﬁcacy and Safety in Clinical
Trials (ENEST) studies assessing TFR in nilotinib-treated patients:
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ENESTop, ENESTgoal and ENESTpath in distinct populations of
patients administered second-line nilotinib.15–17 The ongoing
single-arm, phase 2 ENESTfreedom trial is the ﬁrst study to assess
speciﬁcally the potential for patients with sustained DMR during
frontline nilotinib to stop treatment. Here we present the ﬁrst
results and the results of the primary end point analysis from
ENESTfreedom with a minimum follow-up of 48 weeks after
stopping nilotinib.
MATERIALS AND METHODS
Patients, study design and treatment
Patients (aged ⩾ 18 years) with Philadelphia chromosome-positive
CML-CP who had ⩾ 2 years of frontline treatment with nilotinib and
achieved MR4.5 (BCR-ABL1IS⩽ 0.0032%; determined by a designated
laboratory (MolecularMD, Portland, OR, USA) in a sample with ⩾ 32 000
ABL1 copies) were eligible. Evidence of typical BCR-ABL1 transcripts (that is,
b3a2 (e14a2) and/or b2a2 (e13a2)) at the time of diagnosis was required.
Patients who had previously received other BCR-ABL1 TKIs (cumulative
duration 44 weeks) or interferon-alfa (any duration) or were unable to
tolerate a minimum dose of nilotinib 400 mg once daily were not eligible.
Upon enrollment all patients entered a 1-year consolidation phase
during which they continued nilotinib treatment (Figure 1). Molecular
responses were assessed every 12 weeks during the year of consolidation
treatment by real-time quantitative polymerase chain reaction (RQ-PCR);
sustained DMR was deﬁned as MR4.5 in the last assessment, no assessment
worse than MR4 and⩽ 2 assessments between MR4 and MR4.5. Patients
with sustained DMR throughout the consolidation phase were eligible to
enter the TFR phase and stop nilotinib treatment. Patients with loss of
MMR during the TFR phase were required to reinitiate nilotinib 300 mg two
times daily (or their previously tolerated dose) in the treatment reinitiation
phase. Patients who did not sustain DMR during the consolidation phase
remained on nilotinib treatment (continuation phase; Supplementary
Appendix).
Study end points and assessments
The primary efﬁcacy end point was the proportion of patients who were in
MMR without reinitiation of treatment at week 48 of the TFR phase.
Secondary end points included the proportion of patients who were in
MR4.5 and off treatment at 48 weeks from the start of the TFR phase,
treatment-free survival (TFS) over time (deﬁned as the time from the start
of TFR until the earliest occurrence of any of the following: loss of MMR,
reinitiation of nilotinib for any reason, progression to accelerated phase
(AP)/blast crisis (BC) or death because of any cause), reachievement of
MMR and MR4.5 after nilotinib reinitiation and safety.
Molecular responses were measured as ratios of BCR-ABL1 to ABL1
expressed on the IS, determined from RQ-PCR assessments of peripheral
blood conducted in a central laboratory. During the TFR phase, molecular
responses were evaluated every 4 weeks for the ﬁrst 48 weeks, every
6 weeks for the next 48 weeks and every 12 weeks thereafter. Patients with
loss of MR4 during the TFR phase were monitored every 2 weeks until they
regained MR4, remained in MMR without regaining MR4 for 8 weeks (at
which point the patient received monthly monitoring) or lost MMR and
entered the treatment reinitiation phase. During the treatment reinitiation
phase, molecular responses were evaluated every 4 weeks for the ﬁrst
24 weeks and every 12 weeks thereafter (or as clinically indicated for
patients who had not regained MMR). When sufﬁcient sample was
available, mutational analysis by Sanger sequencing was performed for
patients with loss of MMR, or as clinically indicated.
Adverse events (AEs) were assessed according to the Common
Terminology Criteria for Adverse Events version 4.03. Evaluation of AEs
and laboratory abnormalities were conducted on an ongoing basis on
study and for up to 30 days after the last dose of study treatment or last
day of TFR.
The impact of TFR on patients’ quality of life was assessed as an
exploratory end point. At protocol-deﬁned time points throughout the
study, patient-reported outcomes were collected using the MD Anderson
Symptom Inventory for CML and EuroQol visual analog scale to obtain
overall quality-of-life scores, as well as the EuroQol EQ-5D-5L ques-
tionnaire, in which patients reported the presence or absence and severity
of problems experienced related to mobility, self-care, usual activities,
pain/discomfort and anxiety/depression.18,19
Statistical analyses
The planned sample size was based on Fleming’s single-stage design and
the minimum number of patients required to reject the null hypothesis for
the primary end point (⩽50% TFR rate at 48 weeks). Assuming that ≈30%
of enrolled patients would not qualify for the TFR phase, a minimum
enrollment of 175 patients was required to achieve 90% power to reject
the null hypothesis with a one-sided α-level of 2.5% if the true TFR rate at
48 weeks was ⩾ 65%. With an actual enrollment of 215 patients, the power
increased to 94% with all the other assumptions being the same.
Demographics, baseline characteristics, efﬁcacy and safety results are
reported for patients who entered the TFR phase (that is, the TFR
population). The primary end point was presented as a percentage with an
exact 95% Clopper–Pearson conﬁdence interval (CI). TFS was estimated
using the Kaplan–Meier method; survival time for patients without an
event was censored at the date of the last assessment. Rates of MMR and
MR4.5 regained in the treatment reinitiation phase were reported as
cumulative incidences. An analysis of baseline factors as potential
predictors of TFR maintenance was conducted using a multivariate logistic
regression analysis. The MMR rate at 48 weeks and TFS were also analyzed
in patients who stayed in the TFR phase for ⩾ 24 weeks. The frequencies of
AEs, laboratory abnormalities and predeﬁned groupings of AE types of
special interest were summarized for the TFR population by study phase
(the consolidation phase and the ﬁrst 48 weeks of the TFR phase).
The data presented herein are based on a cutoff date of 30 November
2015, at which time all patients who entered the TFR phase had completed
⩾ 48 weeks of TFR, entered the treatment reinitiation phase or
discontinued the study.
Figure 1. ENESTfreedom study design. aDeﬁned as (in the last 4 quarterly RQ-PCR assessments) MR4.5 in the last assessment, no assessment
worse than MR4 and ⩽ 2 assessments between MR4 and MR4.5.
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Ethics
This study was designed and conducted in accordance with the ICH
Harmonized Tripartite Guidelines for Good Clinical Practice and the ethical
principles of the Declaration of Helsinki. All patients provided written
informed consent before any study procedures and in accordance with
local laws/regulations. The study protocol and amendments were reviewed
by an independent ethics committee or institutional review board for each
study center.
RESULTS
Patients
A total of 231 patients were screened for eligibility between
4 March 2013 and 22 November 2013; 215 of these patients
enrolled and entered the consolidation phase. Two hundred and
three patients completed the consolidation phase, including 190
(88.4%) who entered the TFR phase and 13 who entered the
continuation phase (due to no sustained DMR during
the consolidation phase). Twelve patients discontinued from the
study during the consolidation phase (Figure 2), including two
patients who discontinued with sustained DMR (due to patient
decision). In the TFR population (n= 190), the median time from
ﬁrst achievement of MR4.5 to study entry was 18.3 months, and the
median duration of nilotinib before TFR was 43.5 months (Table 1).
TFR phase
At week 48 of the TFR phase, 98 patients (51.6%; 95% CI, 44.2–58.9
(null hypothesis could not be rejected because of the lower limit
of the 95% CI being ⩽ 50%)) remained in MMR without treatment
reinitiation; of these 98 patients, 5 had conﬁrmed loss of MR4 by
48 weeks (1 of these 5 patients went on to lose MMR after
48 weeks but before the data cutoff date), 3 had loss of MR4.5
without conﬁrmed loss of MR4 and 90 (47.4% of all 190 patients
who stopped treatment; 95% CI, 40.1–54.7) had MR4.5 or better at
48 weeks. Ninety-nine of 190 patients did not have a TFS event by
the data cutoff date (96 remained in TFR and 3 discontinued from
the study (due to patient decision) while in TFR without
experiencing a TFS event and were censored in the analysis),
whereas 91 patients (47.9%) had TFS events (86 entered the
reinitiation phase, 1 died, 3 discontinued TFR without entering the
reinitiation phase (1 due to physician decision and 2 due to loss of
MMR) and 1 lost MMR at TFR week 48 but remained in the TFR
phase at the data cutoff). Most TFS events (70 of 91) occurred
within the ﬁrst 24 weeks (Figure 3); of 120 patients remaining in
TFR at 24 weeks, 98 (81.7%) had MMR at 48 weeks (Supplementary
Figure S1).
Of the 89 patients with loss of MMR while off nilotinib, 72 had
an evaluable mutational assessment, and 1 patient (0.5%) had a
detectable BCR-ABL1 mutation (F359V). Whether this mutation was
pre-existing could not be determined because of the low
BCR-ABL1 copy number in all prior samples collected during the
study; however, the mutation was not detected in samples
collected at initiation of nilotinib therapy and after 2 years on
therapy. This patient regained MMR with nilotinib retreatment,
subsequently lost MMR on nilotinib, and discontinued from the
study owing to the lack of efﬁcacy.
Median age, sex distribution and median durations of nilotinib
and DMR were similar among patients with or without TFR at
Figure 2. Patient disposition. aThree of these patients were still in the continuation phase at the data cutoff date. Of the 10 patients who
completed the continuation phase, 8 were in the TFR-2 phase and 2 remained on nilotinib therapy at the data cutoff date.
Table 1. Baseline characteristics at study entry and nilotinib therapy
before TFR phase entry
TFR population
(n=190)
Baseline characteristics at study entry
Age, median (range) (years) 55.0 (21–86)
Male, n (%) 96 (50.5)
Time from CML diagnosis to study entry, median
(range) (months)
32.2 (21.4–80.7)
Time from achievement of MR4.5 with nilotinib
to study entry, median (range) (months)
18.3 (0.3–70.9)
Nilotinib therapy before TFR phase entry
Duration of nilotinib therapy, median (range)
(months)
43.5 (32.9–88.7)
Actual nilotinib dose intensity during
consolidation phase, median (range)
(mg per day)
600 (400–600)
Abbreviations: CML, chronic myeloid leukemia; MR4.5, molecular response
4.5 (BCR-ABL1⩽ 0.0032% on the International Scale); TFR, treatment-free
remission.
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48 weeks (Supplementary Tables S1 and S2). In a multivariate
logistic regression analysis for TFR at 48 weeks with baseline
factors as explanatory variables in the model, no strong predictors
were formally identiﬁed.
Treatment reinitiation phase
Of the 86 patients who entered the treatment reinitiation phase
(median duration of nilotinib retreatment, 39.6 weeks (range,
5.0–69.7 weeks)), 85 and 76 regained MMR and MR4.5, respectively,
by the data cutoff date (Figure 4). The patient who did not regain
MMR after restarting nilotinib withdrew consent and discontinued
from the study after 7.1 weeks of nilotinib retreatment. Of the nine
patients who regained MMR but not MR4.5 by the data cutoff date,
four remained in the treatment reinitiation phase and ﬁve
discontinued from the study due to AEs (n= 2), lack of efﬁcacy
(n= 1 (patient with F359V mutation)), physician decision (n= 1) or
patient decision (n= 1).
Quality of life
Mean baseline quality-of-life scores were high (mean (s.d.) score at
week 48 of the consolidation phase, which was considered the
baseline for the TFR phase: MD Anderson Symptom Inventory for
CML severity, 1.4 (1.41); MD Anderson Symptom Inventory for CML
interference, 1.7 (2.31); EuroQol visual analog scale, 80.5 (15.61)).
Minimal changes in quality-of-life scores after stopping or
reinitiating treatment were detected among evaluable patients.
The proportions of patients reporting problems in each dimension
of the EQ-5D-5L tended to be similar across study phases,
although a slightly higher proportion of patients reported
problems (of any severity) with pain/discomfort after stopping
treatment (49.0% of evaluable patients reported problems at week
48 of the consolidation phase compared with 58.1% at week 12 of
the TFR phase).
Safety
No patients progressed to AP/BC. Five deaths were reported by
the data cutoff date: two deaths occurred during the consolida-
tion phase (one cardiac arrest and one suicide), one occurred
during the TFR phase (unknown cause) and two occurred during
the treatment reinitiation phase (one acute myocardial infarction
and one due to an unknown cause).
Among patients who entered the TFR phase, AEs were reported
in 83.2% during the 1-year consolidation phase (grade 3/4 in
13.7%) and in 65.8% during the ﬁrst 48 weeks of the TFR phase
(grade 3/4 in 11.1%). The most common AEs during the
consolidation and TFR phases were nasopharyngitis (11.1%) and
arthralgia (12.1%), respectively (Table 2). Elevations in glucose,
alanine aminotransferase, aspartate aminotransferase, bilirubin
and lipase were less common in the TFR phase than in the
consolidation phase. Most patients with laboratory abnormalities
during the TFR phase had experienced the same abnormalities
during the consolidation phase. No notable differences in
hematologic abnormalities were reported during the consolida-
tion phase compared with the TFR phase (Table 2). Cardiovascular
events (CVEs) were reported in four patients (2.1%) during the
consolidation phase (ischemic heart disease (n= 2), ischemic
cerebrovascular event and peripheral artery disease (n= 1 each))
and in ﬁve patients (2.6%) during the TFR phase (ischemic
cerebrovascular events and peripheral artery disease (n= 2 each)
and arteriosclerosis (n= 1), all of which were ﬁrst reported during
the ﬁrst 24 weeks of the TFR phase; Table 3). One patient had CVEs
reported during both the consolidation and TFR phases. No
patient in the TFR population discontinued from the study
because of a CVE.
Forty-seven patients (24.7%) had AEs in a predeﬁned muscu-
loskeletal pain grouping (consisting of AEs reported as muscu-
loskeletal pain, myalgia, pain in extremity, arthralgia, bone pain
and spinal pain) during the ﬁrst 48 weeks of the TFR phase
compared with 31 patients (16.3%) during the 1-year consolida-
tion phase. Of the 47 patients with musculoskeletal pain-related
Figure 3. Kaplan–Meier estimate of TFS among all patients who
entered the TFR phase. TFS was deﬁned as the time from the start of
TFR until the earliest of any of the following: loss of MMR, reinitiation
of nilotinib for any reason, progression to AP/BC or death because of
any cause.
Figure 4. Cumulative incidence of (a) MMR and (b) MR4.5 regained
after nilotinib reinitiation.
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events in the TFR phase, 45 had grade 1/2 events and 2 had grade
3 events (none led to study discontinuation; including 1 patient
with grade 3 arthralgia and 1 patient with 2 episodes of grade 3
bone pain); musculoskeletal pain-related events were more
frequent in female (33.0%) than in male patients (18.8%) during
the TFR phase (Table 4). Thirty-two of the 47 patients had no
history of musculoskeletal pain in the consolidation phase or
before enrollment. Most AEs in the musculoskeletal pain grouping
(n= 39) were reported within 24 weeks of stopping nilotinib.
The Kaplan–Meier-estimated median duration of these AEs was
24.0 weeks (95% CI, 10.1 weeks—not estimable).
DISCUSSION
In ENESTfreedom, 51.6% (95% CI, 44.2–58.9) of patients remained
in remission at 48 weeks after stopping nilotinib, consistent with
results from other TFR studies following long-term TKI
treatment.4,7–13 As the prespeciﬁed statistical null hypothesis
(TFR rate⩽ 50%) could not be rejected because of the lower limit
of the 95% CI being ⩽ 50%, the primary end point failed
statistically. This is a result of selecting too high of a threshold
(50%) for the TFR rate in the null hypothesis, which was due to an
underestimation of the impact of the TKI treatment duration on
TFR rate at the time the protocol was developed. Nonetheless, the
observed TFR rate of 51.6% is a clinically important outcome,
particularly when considering the relatively short duration of prior
nilotinib therapy (3.6 years) among patients in the study and the
association between duration of TKI therapy and TFR probability in
prior studies.4,10 Comparison of results across TFR trials is limited
by study design variations (for example, depth/duration of DMR
required before stopping treatment, minimal duration of TKI
therapy before stopping treatment and deﬁnition of loss of
remission); however, the ability to remain in remission after
stopping TKI therapy has been consistently demonstrated in
patients with sustained DMR on long-term TKI treatment.4,6–13 In
EURO-SKI, among 772 patients eligible to stop imatinib, nilotinib
or dasatinib after a median treatment duration of 91 months and
with MR4 sustained for ⩾ 1 year, molecular relapse-free survival at
12 months was 56% (95% CI, 52–59).10
Stopping frontline nilotinib was safe in ENESTfreedom: no new
safety signals were identiﬁed during treatment, nearly all patients
who reinitiated nilotinib after loss of MMR regained MMR (98.8%)
and MR4.5 (88.4%) rapidly, and no patient progressed to AP/BC.
The majority of patients with loss of MMR lost the response within
Table 2. Frequently reported AEs and laboratory abnormalities in the
TFR population during the consolidation and TFR phases
Patients, n (%) Consolidation phase
(n=190)a
TFR phase
(n=190)a
Any grade Grade 3/4 Any grade Grade 3/4
AEs reported in 45% of patients in the consolidation or TFR phase
Nasopharyngitis 21 (11.1) 0 16 (8.4) 0
Arthralgia 16 (8.4) 0 23 (12.1) 2 (1.1)
Hypertension 15 (7.9) 10 (5.3) 7 (3.7) 2 (1.1)
Diarrhea 11 (5.8) 0 8 (4.2) 1 (0.5)
Headache 10 (5.3) 0 10 (5.3) 0
Pain in extremity 5 (2.6) 0 12 (6.3) 0
Key hematologic abnormalities based on CTCAE grades of laboratory
values
Anemia 46 (24.2) 0 38 (20.0) 1 (0.5)
Lymphopenia 17 (8.9) 1 (0.5) 26 (13.7) 0
Thrombocytopenia 16 (8.4) 0 20 (10.5) 0
Leukopenia 5 (2.6) 0 11 (5.8) 1 (0.5)
Key biochemical abnormalities based on CTCAE grades of laboratory
values
Elevated glucose 75 (39.5) 1 (0.5) 37 (19.5) 1 (0.5)
Elevated ALT 71 (37.4) 0 24 (12.6) 0
Elevated AST 30 (15.8) 0 13 (6.8) 0
Elevated bilirubin 57 (30.0) 3 (1.6) 6 (3.2) 0
Elevated lipase 57 (30.0) 6 (3.2) 22 (11.6) 3 (1.6)
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; CTCAE, Common Terminology Criteria for
Adverse Events; TFR, treatment-free remission. aMedian duration of study
treatment during the consolidation phase among patients in the TFR
population was 52 weeks, and the duration of the TFR phase was 48 weeks.
Table 3. AE groups of special interesta
Patients, n (%) Consolidation
phase (n= 190)b
TFR phase
(n=190)b
Musculoskeletal painc 31 (16.3) 47 (24.7)
Fluid retention 4 (2.1) 8 (4.2)
Cardiovascular events 4 (2.1) 5 (2.6)
Ischemic cerebrovascular events 1 (0.5) 2 (1.1)
Ischemic heart disease 2 (1.1) 0
Peripheral artery disease 1 (0.5) 2 (1.1)
Others 0 1 (0.5)
Rash 8 (4.2) 2 (1.1)
Pancreatitis 3 (1.6) 0
Abbreviations: AE, adverse event; TFR, treatment-free remission. aEach
listed AE group includes a predeﬁned set of individual AEs. Reported
frequencies include all patients with ⩾ 1 AE in the group. bMedian duration
of study treatment during the consolidation phase among patients in the
TFR population was 52 weeks, and the duration of the TFR phase was
48 weeks. cDeﬁned as any of the following AEs: musculoskeletal pain,
myalgia, pain in extremity, arthralgia, bone pain and/or spinal pain.
Table 4. Rate of musculoskeletal pain-related events reported during
the TFR phase according to baseline characteristics
Patients, n/N (%)a Rate of musculoskeletal
pain-related events
Ageb
o55 years 23/94 (24.5)
⩾ 55 years 26/96 (27.1)
Sex
Female 31/94 (33.0)
Male 18/96 (18.8)
Time from achievement of MR4.5 until TFR phase entryb
o30.37 months 24/95 (25.3)
⩾ 30.37 months 25/95 (26.3)
Duration of nilotinib before TFR phase entryb
o43.47 months 22/94 (23.4)
⩾ 43.47 months 27/96 (28.1)
Musculoskeletal pain-related events before TFR phase entryc
Yes 15/49 (30.6)
No 34/141 (24.1)
Abbreviations: MR4.5, molecular response 4.5 (BCR-ABL1⩽ 0.0032% on the
International Scale); TFR, treatment-free remission. aRates of musculoske-
letal pain-related events reported during the TFR phase are shown as a
percentage of patients within each subgroup. bSubgroups were deﬁned
based on the median values for each parameter. cIncludes events in patient
history before study entry or reported during the consolidation phase.
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6 months of stopping nilotinib, highlighting the importance of
frequent monitoring of patients who stop TKI therapy to ensure
timely retreatment. One patient with loss of MMR during the TFR
phase was found to have a detectable mutation; however, without
serial testing of prior samples, the signiﬁcance of this ﬁnding is
unclear because the mutation may have been present before the
patient started the TFR phase. Additionally, because low-level
mutations can be undetectable using Sanger sequencing,20 it is
possible that other patients may have had kinase domain
mutations below the limit of detection. However, the emergence
of BCR-ABL1 mutations may be less likely during the TFR phase
because of the absence of TKI-induced selective pressure for
mutants. Kinase domain mutations have not been reported in
other TFR studies.4,6–13
Although long-term safety/tolerability considerations are moti-
vators for stopping treatment in some patients,3–5 the rates of
some AEs (for example, hematologic abnormalities and CVEs) were
similar in the ﬁrst 48 weeks of the TFR phase compared with the
consolidation phase. This may be due to the fact that this study
enrolled patients who had already received nilotinib for multiple
years and had established tolerance of nilotinib. Further follow-up
is required to determine whether the risk of CVEs and other AEs
decreases over time after stopping treatment. In addition, the
frequency of low-grade musculoskeletal pain-related events
increased during the ﬁrst year of the TFR phase, consistent with
prior reports in patients who stopped imatinib therapy.4,21–24
In subanalyses of (mostly imatinib-treated) patients from EURO-
SKI, ~ 1/3 experienced musculoskeletal pain after stopping
treatment.21,22,24 Similar events were retrospectively described in
30% (n= 27/90) of patients in the Korean Imatinib Discontinuation
study.4 Similar to the ﬁndings in ENESTfreedom, the majority of
these events were reported within 6 months of stopping therapy.4
Many of these events were self-limiting, resolving within
12 months, although some events continued beyond 1 year.4,21
No impact of stopping treatment on patients’ overall quality of
life was detected. This may be due to patients having a relatively
high quality of life before treatment discontinuation; it may also
result from the use of questionnaires that were not optimal for
assessment of patients doing well on treatment.
Recent reviews by Saussele et al.25 and Hughes and Ross26 have
discussed potential criteria for identifying patients who may be
candidates for TFR and recommendations for monitoring of
patients during TFR based on available data from clinical trials to
date. Both reviews highlight the importance of sustained
DMR before stopping treatment and of frequent patient monitor-
ing, including quantiﬁcation of typical BCR-ABL1 transcript levels
by a well-validated assay run in an IS-standardized center
following established guidelines for measuring DMR.27 Identiﬁca-
tion of additional prognostic criteria for TFR remains under
investigation.25,26 Although no strong prognostic factors were
detected in this study, the analysis may have been limited by the
size and relative homogeneity of the population (for example,
most patients had a similar prior treatment duration).
Frontline nilotinib therapy is known to result in rapid and high
rates of DMR28,29 —a key prerequisite for TFR.4,6–13 In ENEST1st,
55.2% (n= 581/1052) and 38.6% (n= 406/1052) of patients
achieved MR4 and MR4.5, respectively, by 2 years with frontline
nilotinib.29 In ENESTnd, more than half of patients treated with
frontline nilotinib 300 mg two times daily achieved MR4.5 by 5
years (n= 151/282; 54%), compared with 31% of patients treated
with frontline imatinib (n= 89/283).28 Furthermore, with 6 years of
follow-up in ENESTnd, 38% (n= 107/282) of patients in the
nilotinib 300-mg twice-daily arm vs 22% (n= 61/283) in the
imatinib arm met the treatment duration and sustained
DMR requirements deﬁning eligibility to attempt TFR in
ENESTfreedom.30 These data suggest that frontline nilotinib may
increase the number of patients who become eligible to
discontinue treatment.
When selecting a TKI for frontline therapy, several factors must
be considered: in addition to the efﬁcacy and safety proﬁles of
each available treatment option, treatment cost can be an
important consideration, particularly with the introduction of
generic imatinib; now, the increased potential for TFR eligibility
with nilotinib (and the potential cost savings through treatment
discontinuation31–33) may be additional factors to consider for
some patients when selecting a frontline TKI. These long-term
considerations are increasingly important as patients with CML
now have a life expectancy comparable to that of the general
population.34
As the ﬁrst study to speciﬁcally investigate TFR following
frontline nilotinib, ENESTfreedom can provide important new
information on this emerging treatment goal for patients with
CML-CP. Here, the ﬁrst results from ENESTfreedom demonstrate
that a clinically signiﬁcant percentage of patients (51.6%) with
sustained DMR on frontline nilotinib therapy and a median
treatment duration of 43.5 months were able to remain in MMR
for ⩾ 48 weeks after stopping nilotinib. The results from
ENESTfreedom, together with the results from ENESTnd showing
higher rates of DMR and sustained DMR with nilotinib vs
imatinib,28,30 suggest that more patients may become eligible to
stop treatment and sustain remission following frontline nilotinib
therapy than following imatinib therapy. Additional follow-up and
analyses of TFR data in ENESTfreedom and other TFR studies will
be needed to further evaluate the patient, disease and treatment
characteristics before stopping treatment that may be associated
with maintaining TFR, as well as the long-term durability of TFR.
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